Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pieris Pharmaceuticals (PIRS)
NASDAQ:PIRS
Pieris Pharmaceuticals (PIRS) Stock Price & Analysis
581 Followers
PIRS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.60 - $80.86
Previous Close$11.33
Volume3.36K
Average Volume (3M)14.79K
Market Cap
$13.88M
Enterprise Value-$18.51M
Total Cash (Recent Filing)$44.81M
Total Debt (Recent Filing)$12.29M
Price to Earnings (P/E)-0.5
Beta1.26
Next Earnings
May 08, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.94
Shares Outstanding1,236,688
10 Day Avg. Volume22,506
30 Day Avg. Volume14,789
Standard Deviation0.25
R-Squared0.01
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.45
Price to Sales (P/S)2.40
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.38
Enterprise Value/Gross Profit-0.71
Enterprise Value/Ebitda-1.55
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Pieris Pharmaceuticals News
PremiumCompany Announcements
Pieris Pharmaceuticals Enacts Reverse Stock Split for NASDAQ Compliance
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PIRS FAQ
What was Pieris Pharmaceuticals’s price range in the past 12 months?
Pieris Pharmaceuticals lowest stock price was $10.60 and its highest was $80.86 in the past 12 months.
What is Pieris Pharmaceuticals’s market cap?
Currently, no data Available
When is Pieris Pharmaceuticals’s upcoming earnings report date?
Pieris Pharmaceuticals’s upcoming earnings report date is May 08, 2024 which is 7 days ago.
How were Pieris Pharmaceuticals’s earnings last quarter?
Pieris Pharmaceuticals released its earnings results on Mar 27, 2024. The company reported -$3.706 earnings per share for the quarter, beating the consensus estimate of -$9.6 by $5.894.
Is Pieris Pharmaceuticals overvalued?
According to Wall Street analysts Pieris Pharmaceuticals’s price is currently Overvalued.
Does Pieris Pharmaceuticals pay dividends?
Pieris Pharmaceuticals does not currently pay dividends.
What is Pieris Pharmaceuticals’s EPS estimate?
Pieris Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pieris Pharmaceuticals have?
Pieris Pharmaceuticals has 1,236,688 shares outstanding.
What happened to Pieris Pharmaceuticals’s price movement after its last earnings report?
Pieris Pharmaceuticals reported an EPS of -$3.706 in its last earnings report, beating expectations of -$9.6. Following the earnings report the stock price went up 0.906%.
Which hedge fund is a major shareholder of Pieris Pharmaceuticals?
Among the largest hedge funds holding Pieris Pharmaceuticals’s share is Platinum Investment Management. It holds Pieris Pharmaceuticals’s shares valued at N/A.
---
Pieris Pharmaceuticals Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
PIRS Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 12.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.53%
12-Months-Change
Fundamentals
Return on Equity
-89.76%
Trailing 12-Months
Asset Growth
-59.49%
Trailing 12-Months
Company Description
Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
---
PIRS Earnings Call
Q1 2023
0:00 / 0:00
---
Technical Analysis
---